<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260606069671N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-06-12</date_registration>
      <primary_sponsor>Tabriz University</primary_sponsor>
      <public_title>The effect of group psycotherapy of acceptance and commitment on sexual interest and arousal problems</public_title>
      <acronym>ACT</acronym>
      <scientific_title>Investigation the effectiveness of acceptance and commitment group intervention on sexual avoidance, sexual satisfaction, marital happiness, and quality of life in individuals with sexual interest/arousal disorder</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>75</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/90750</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: After completion of baseline assessments, eligible participants will be randomly allocated in equal proportions to the Acceptance and Commitment Therapy (ACT) group, attention-control group, and no-intervention control group using block randomization with a fixed block size of six. The random allocation sequence will be generated using Random Allocation Software. Participants will be assigned according to the pre-generated random sequence to ensure balance in group sizes throughout the recruitment process.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Sexual Interest/Arousal Disorder.</hc_freetext>
      <i_freetext>Intervention 1: Intervention Group 1: Participants will receive eight weekly 90-minute group-based Acceptance and Commitment Therapy sessions. The intervention is based on the Hexaflex model and includes acceptance of internal experiences, cognitive defusion, present-moment awareness, self-as-context, values clarification, and committed action in the context of intimate relationships and sexual concerns. Sessions will be conducted in a group format by a trained therapist. Intervention 2: Intervention Group 2: Participants will receive eight weekly 90-minute supportive and educational sessions. Session content includes general mental health education, stress management, sleep hygiene, communication skills, and sexual health literacy. These sessions are matched to the intervention group in terms of number and duration but do not include the specific therapeutic components of Acceptance and Commitment Therapy. Intervention 3: Control group: Participants will receive no psychological or educational intervention during the study period and will only take part in the assessment procedures. After completion of the study, they will be offered the therapeutic intervention if they wish to receive it.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
De-identified individual participant data. The dataset will include demographic characteristics, baseline data, primary and secondary outcome measures, and variables required to reproduce the study findings. All personal identifiers will be removed prior to data sharing. Data will be available after publication of the primary study results upon reasonable request, submission of a scientific rationale, and approval by the corresponding author.

When:
After publishing the paper

To whom:
Researchers, faculty members, graduate students, research institutions, academic centers, and other applicants with legitimate scientific and research purposes may request access to the study data and documents. Requests will be reviewed based on the intended use of the data and will be granted upon approval by the corresponding author and in accordance with ethical and confidentiality requirements.

Conditions:
The study data and documents may be used solely for scientific, research, and educational purposes. Applicants must provide a written description of the intended use of the data, research question, analytical approach, and planned use of the documents. The data may not be used to identify participants, for commercial purposes, transferred to third parties without permission, or used in any manner inconsistent with research ethics principles. All data will be provided in a de-identified format, and recipients will be required to maintain confidentiality and appropriately acknowledge the original study in all reports and publications arising from the shared data.

Where to obtain:
contacting the corresponding author
mirlohianm@gmail.com

How to obtain:
Applicants should submit their requests by email to the corresponding author. The request should include the applicant’s details, institutional affiliation, the purpose of the data or document use, the research question, and the analysis plan. Requests will be reviewed for scientific merit, ethical considerations, and confidentiality requirements. A decision will be communicated within 4 weeks. If approved, the requested data or documents will be provided in an appropriate format after removal of all identifying information and shared via email or another secure transfer method.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Majid Mahmoud Alilou</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>22 Bahman blvd, Tabriz</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166616471</zip>
        <telephone>+98 41 3334 0081</telephone>
        <email>M-alilou@tabrizu.ac.ir</email>
        <affiliation>Tabrzi University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Abai Bkhshipour Roudsari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>22 Bahman blvd, Tabriz</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166616471</zip>
        <telephone>+98 41 3334 0081</telephone>
        <email>bakhshipour@tabrizu.ac.ir</email>
        <affiliation>Tabriz University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Diagnosis of sexual interest/arousal disorder based on clinical interview and DSM-5 criteria
Being married
Having at least a high school diploma
Not receiving concurrent psychotherapeutic interventions targeting sexual functioning
Not receiving concurrent pharmacological treatments affecting sexual functioning
No severe physical illness affecting sexual functioning
No severe psychiatric disorder based on clinical interview</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>45 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Presence of severe psychiatric disorders based on clinical interview
Presence of severe physical illnesses affecting sexual functioning
Concurrent participation in psychotherapeutic interventions targeting sexual problems
Concurrent use of medications affecting sexual functioning
Inability to regularly attend treatment sessions</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F52.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Sexual arousal disorders</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Behavior</i_code>
      <i_code>Placebo</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention Group 1: Participants will receive eight weekly 90-minute group-based Acceptance and Commitment Therapy sessions. The intervention is based on the Hexaflex model and includes acceptance of internal experiences, cognitive defusion, present-moment awareness, self-as-context, values clarification, and committed action in the context of intimate relationships and sexual concerns. Sessions will be conducted in a group format by a trained therapist.</i_keyword>
      <i_keyword>Intervention Group 2: Participants will receive eight weekly 90-minute supportive and educational sessions. Session content includes general mental health education, stress management, sleep hygiene, communication skills, and sexual health literacy. These sessions are matched to the intervention group in terms of number and duration but do not include the specific therapeutic components of Acceptance and Commitment Therapy.</i_keyword>
      <i_keyword>Control group: Participants will receive no psychological or educational intervention during the study period and will only take part in the assessment procedures. After completion of the study, they will be offered the therapeutic intervention if they wish to receive it.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Sexual Avoidance Score. Timepoint: Before the intervention, immediately after the end of the 8 intervention sessions, and 3 months after the end of the intervention. Method of measurement: Rost and Glombok Sexual Satisfaction Questionnaire, Sexual Avoidance Subscale.</prim_outcome>
      <prim_outcome>Sexual satisfaction score. Timepoint: Before the intervention, immediately after the end of the 8 intervention sessions, and 3 months after the end of the intervention. Method of measurement: Larson Sexual Satisfaction Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Quality of life score. Timepoint: Before the intervention, immediately after the end of the 8 intervention sessions, and 3 months after the end of the intervention. Method of measurement: World Health Organization Quality of Life Questionnaire, short version.</sec_outcome>
      <sec_outcome>Marital happiness score. Timepoint: Before the intervention, immediately after the end of the 8 intervention sessions, and 3 months after the end of the intervention. Method of measurement: Azerin Marital Happiness Questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-05-24</approval_date>
        <contact_name>Ethics committee of Tabriz University</contact_name>
        <contact_address>22 Bahman Blvd, Tabriz Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
